Literature DB >> 22923363

[Profile of Buruli ulcer treated at the National Reference Centre of Togo: a study of 119 cases].

B Saka1, D E Landoh, B Kobara, K E Djadou, I Yaya, K B Yékplé, E Piten, A Balaka, S Akakpo, K Kombaté, A Mouhari-Toure, K Kanassoua, P Pitché.   

Abstract

The purpose of this study was to describe the epidemiological, clinical, therapeutic profile and the outcome of Buruli ulcer (BU) in the National Reference Center for Buruli ulcer treatment (NRCBUT) in Togo. It was a retrospective and descriptive study of records of patients treated for BU in the NRCBUT between June 2007 and December 2010. During the study period, 119 patients (56.3% males) were treated in the NRCBUT for BU. The median age of patients was 14 years. The proportion of children (< 15 years) was 56.3%. On admission, 85 patients were at ulcer stage and 34 patients at the pre-ulcer stage. BU wounds were mainly located on lower limbs (50.4%), followed by upper limbs (32.6%) and trunk (13.3%). The location of the wounds on the lower limbs were more frequent in patients older than 15 years (P < 0.001), while those on the upper limbs (P = 0.002) and trunk (P = 0.03) were more frequent in patients aged less than 15 years. All patients had received medical treatment which was based on rifampicin-streptomycin combination for eight weeks. This treatment was coupled to surgery in 30 cases. The outcome was punctuated by complications in 7 patients, limb amputation in 3 patients, and sequels in 10 patients. This study confirmed that the BU is the prerogative of young subjects and the exposed areas in the skin facilitates transmission. Apart from these classic features, some unique aspects including the age-dependent distribution are related to the pathogenesis of this disease.

Entities:  

Mesh:

Year:  2012        PMID: 22923363     DOI: 10.1007/s13149-012-0241-1

Source DB:  PubMed          Journal:  Bull Soc Pathol Exot        ISSN: 0037-9085


  6 in total

1.  Buruli ulcer control in a highly endemic district in Ghana: role of community-based surveillance volunteers.

Authors:  Kabiru Mohammed Abass; Tjip S van der Werf; Richard O Phillips; Fred S Sarfo; Justice Abotsi; Samuel Osei Mireku; William N Thompson; Kingsley Asiedu; Ymkje Stienstra; Sandor-Adrian Klis
Journal:  Am J Trop Med Hyg       Date:  2014-10-20       Impact factor: 2.345

Review 2.  Clinical efficacy of Rifampicin and Streptomycin in combination against Mycobacterium ulcerans infection: a systematic review.

Authors:  Marius Zambou Vouking; Violette Claire Tamo; Carine Nouboudem Tadenfok
Journal:  Pan Afr Med J       Date:  2013-08-29

3.  Mycobacterium ulcerans Disease with Unusual Sites Not to Be Ignored.

Authors:  Sangaré Abdoulaye; Kourouma Sarah Hamdan; Kouassi Yao Isidore; Ecra Elidjé Joseph; Kaloga Mamadou; Gbery Ildevert Patrice
Journal:  Dermatol Res Pract       Date:  2014-10-16

4.  A case of squamous cell carcinoma occurring on a scar of Buruli ulcer in Bouake, Ivory Coast.

Authors:  Almamy Diabaté; Koffi Kouamé Pacôme Gbandama; Amon Anderson Stephen Kouabenan; Irenée Gué; Bamba Vagamon; Boussou Romain Aka
Journal:  Pan Afr Med J       Date:  2019-07-23

Review 5.  Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease).

Authors:  Rie R Yotsu; Marty Richardson; Norihisa Ishii
Journal:  Cochrane Database Syst Rev       Date:  2018-08-23

6.  Geographic distribution, age pattern and sites of lesions in a cohort of Buruli ulcer patients from the Mapé Basin of Cameroon.

Authors:  Martin W Bratschi; Miriam Bolz; Jacques C Minyem; Leticia Grize; Fidèle G Wantong; Sarah Kerber; Earnest Njih Tabah; Marie-Thérèse Ruf; Ferdinand Mou; Djeunga Noumen; Alphonse Um Boock; Gerd Pluschke
Journal:  PLoS Negl Trop Dis       Date:  2013-06-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.